Physician profile
Wayne C Lue
NPI 1922068428
$3,109.97
in general payments reported to CMS, 2019-2025
31 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $139 · 2021: $573 · 2022: $712 · 2023: $614 · 2024: $181 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.67 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.83 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $436.12 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.17 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $121.69 | 2019-2025 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $119.53 | 2022 | |
| Redhill Biopharma INC. | $112.46 | 2020-2021 | |
| Endogastric Solutions, INC | $107.84 | 2021 | |
| Pfizer INC. | $92.43 | 2019-2022 | |
| Ardelyx, INC. | $90.77 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $66.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $58.35 | 2019-2020 | |
| Vivus LLC | $54.46 | 2022-2024 | Pancreaze |
| Merck Sharp & Dohme LLC | $47.25 | 2020-2022 | |
| Celltrion USA INC. | $40.09 | 2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $35.55 | 2019-2024 | Entyvio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $35.23 | 2021-2022 | |
| Mauna Kea Technologies, INC. | $28.58 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.43 | 2019 | |
| Allergan, INC. | $22.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.53 | 2024 | Voquezna |
| Evoke Pharma, INC. | $20.37 | 2024 | |
| Shionogi INC | $19.87 | 2019 | |
| Gilead Sciences, INC. | $18.99 | 2019 | |
| Lilly USA, LLC | $18.45 | 2024 | Omvoh |
| Rigel Pharmaceuticals, INC. | $17.85 | 2020 | |
| Clovis Oncology, INC. | $16.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.17 | 2023 | Rebyota |
| Shire North American Group INC | $13.44 | 2019 | |
| Braintree Laboratories, INC. | $13.08 | 2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $12.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,666.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Lue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.